Safety
GLP-1 medicines before surgery or sedation
GLP-1 treatment can delay gastric emptying, and the current labels warn about pulmonary aspiration during general anesthesia or deep sedation. The procedure team needs to know about treatment in advance.
Why the stomach matters
Aspiration occurs when stomach contents enter the airways. Labels report this concern in people taking GLP-1 medicines during procedures involving anesthesia or deep sedation, including cases despite reported fasting.
The label warning does not establish one medicine-hold interval that is right for every procedure and patient. Stomach symptoms, escalation, other medical conditions, diabetes control, and the planned anesthesia can affect the decision.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information · Foundayo prescribing information
Information to give the procedure team
Provide the exact brand or compounded formulation, route, dose, date of the last dose, and whether you recently started or escalated. Describe nausea, vomiting, bloating, severe constipation, or other stomach symptoms honestly.
Tell the team about diabetes medicines and prior low-glucose problems. If a medicine is withheld, diabetes management or another treatment objective may need a plan. A clinic's general scheduling advice is not a substitute for the anesthesia team's assessment.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Mounjaro prescribing information
Follow the coordinated instructions
Ask the anesthesia team and prescriber to agree on fasting, medication timing, and any additional precautions. This page intentionally does not prescribe a universal day-count hold rule from an older internet article.
Contact the procedure team if symptoms, dosing, or the planned procedure change. Do not skip, restart, or take an extra dose on your own to fit a calendar. A long interruption may require re-escalation and should be discussed before resuming treatment.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information
Restarting after the procedure
Ask when it is appropriate to resume the exact product, particularly if food and fluid intake remain limited or significant nausea continues. The former maintenance dose is not automatically the correct restart after a lengthy interruption.
Keep both teams informed about complications or symptoms. Manufacturer instructions and clinical judgment should guide the plan; a medication review site cannot account for the individual anesthesia and metabolic risks.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Mounjaro prescribing information · Zepbound prescribing information
What current multi-society guidance emphasizes
The multi-society guidance summarized by the American Society of Anesthesiologists advises that most patients can continue GLP-1 treatment before elective procedures, with individualized assessment for higher-risk situations. It discusses measures such as a liquid-only diet for 24 hours, adjusting the anesthesia plan, and point-of-care gastric ultrasound when appropriate. These are decisions for the procedure team, not instructions to start a liquid diet or alter medication independently.
The guidance considers the balance between aspiration concerns and the consequences of withholding treatment, including glucose effects in diabetes. Higher-risk circumstances include escalation and significant gastrointestinal symptoms. The medicine labels also warn about aspiration during general anesthesia or deep sedation. A universal instruction to stop every weekly dose seven days before every procedure oversimplifies the current approach.
Sources: ASA: multi-society guidance on GLP-1 medicines before procedures · Wegovy prescribing information, including tablets and Wegovy HD · Zepbound prescribing information
Share information early enough to change the plan
Tell the team the full product name, route, current dose, last administration, recent increases, and gastrointestinal symptoms. Include medicines obtained through telehealth or a compounding pharmacy. A procedure questionnaire asking only about injections can miss daily tablets, while a general medication list saying "weight-loss medicine" may omit the details needed for assessment.
For example, someone recently escalating and experiencing persistent fullness may need a different procedure discussion from someone stable on treatment without symptoms. That example does not determine whether either person should continue or hold the drug. The anesthesia, procedural, and prescribing teams should coordinate the decision. Ask for written medicine and fasting instructions, and report new symptoms or a dose change after those instructions were issued.
Sources: ASA: multi-society guidance on GLP-1 medicines before procedures · Wegovy prescribing information, including tablets and Wegovy HD · Foundayo prescribing information
Include diabetes management and restart in the written plan
If withholding treatment is recommended, ask who manages glucose when relevant and when the medicine can resume. A missed dose for a procedure still needs the product's rules, and a prolonged interruption may require lower-dose re-escalation. Food and fluid intake after the procedure, ongoing nausea, and complications can affect the clinical decision.
Do not restart an old maintenance dose solely because the procedure is over or compensate for a held dose with an extra one. Keep the prescriber informed of the actual last dose and recovery circumstances. If the procedure is urgent, tell the team about treatment immediately rather than attempting to delay disclosure until a medication interval has passed. The procedure team can evaluate the situation with the information available; a review page cannot account for individual aspiration and metabolic risk.
Sources: ASA: multi-society guidance on GLP-1 medicines before procedures · Wegovy prescribing information, including tablets and Wegovy HD · Mounjaro prescribing information · Zepbound prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.